¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Exposure to controlled fire, not in building or structure"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • host-controlled modification
    ¼÷ÁÖÁ¶Àý¼ö½Ä
  • pressure-controlled ventilation
    ¾Ð·ÂÁ¶Àýȯ±â
  • pressure-controlled ventilator
    ¾Ð·ÂÁ¶ÀýÇüȯ±â±â
  • patient-controlled analgesia
    ÀÚ°¡Á¶ÀýÁøÅë
  • randomized controlled trial
    ¹«ÀÛÀ§´ëÁ¶½ÃÇè
  • self-controlled anesthesia
    ÀÚ°¡Á¶Àý¸¶Ãë
  • accidental exposure
    »ç°íÇÇÆø, »ç°í³ëÃâ
  • acute exposure
    ±Þ¼º³ëÃâ
  • cumulative glycemic exposure
    ´©Àû°íÇ÷´ç³ëÃâ
  • chronic exposure
    ¸¸¼º³ëÃâ
  • double exposure technique
    Áߺ¹X¼±ÃÔ¿µ(¼ú)
  • exposure
    1. ³ëÃâ 2. Á¶»ç 3. Á¶»ç¼±·® 4. Æø·Î 5. ÇÇÆø
  • exposure dose
    Æø·Î¼±·®
  • exposure keratitis
    ³ëÃâ°¢¸·¿°
  • exposure rate
    ³ëÃâ·ü, ÇÇÆø·ü
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • alveolar structure
    ²Ê¸®±¸Á¶, ÆóÆ÷±¸Á¶
  • bone structure
    »À±¸Á¶, °ñ±¸Á¶
  • chain structure
    »ç½½±¸Á¶, ¿¬¼â±¸Á¶
  • cognitive structure
    ÀÎÁö±¸Á¶
  • core structure
    Á߽ɱ¸Á¶¹°
  • decidual structure
    Å»¶ô¸·±¸Á¶
  • discoid structure
    ¿ø¹Ý±¸Á¶
  • electron structure
    ÀüÀÚ±¸Á¶
  • immunoglobulin structure
    ¸é¿ª±Û·ÎºÒ¸°±¸Á¶
  • structure activity relationship
    ±¸Á¶È°¼º»ó°ü°ü°è, ±¸Á¶ÀÛ¿ë°ü°è
  • structure
    ±¸Á¶
  • accidental exposure
    »ç°íÇÇÆø, »ç°í³ëÃâ
  • acute exposure
    ±Þ¼ºÇÇÆø, ±Þ¼º³ëÃâ
  • chronic exposure
    ¸¸¼ºÇÇÆø, ¸¸¼º³ëÃâ
  • cumulative glycemic exposure
    ´©Àû°íÇ÷´ç³ëÃâ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • hemoglobin structure
    Ç÷»ö¼Ò±¸Á¶
  • hemomonochorial structure
    Ç÷¾×ȬÃþÀ¶¸ð¸·±¸Á¶
  • immunoglobulin structure
    ¸é¿ª±Û·ÎºÒ¸° ±¸Á¶
  • personality structure, Jungian theory
    Àΰݱ¸Á¶
  • primary structure
    ÀÏÂ÷±¸Á¶(¡­Ï°ðã).
  • pseudoknot RNA structure
    ¸ÅµìÇü RNA ±¸Á¶
  • quasicrystalline structure
    ÁذáÁ¤±¸Á¶(ñÞÌ¿ïÜϰðã).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • controlled hypothermia
    Á¶ÀýÀúü¿Â(¹ý).
  • controlled respiration
    Á¶ÀýÈ£Èí(¹ý)(¡­û¼ýåÛö) ¡ì¸¶Ãë½ÃÀÇ¡í.
  • flow meter controlled vaporizer
    À¯·®Á¶Àý±âÈ­±â.
  • host controlled variation
    ¼÷ÁÖÀÇÁ¸(±ÔÁ¦)º¯ÀÌ.
  • host-controlled modification
    ¼÷ÁÖÁ¶Àý¼ö½Ä
  • induced hypotension =controlled hibernation
    À¯µµ¼º ÀúÇ÷¾Ð(¹ý), Á¶ÀýÀúÇ÷¾Ð(¹ý)(ðàï½î¸úìäâÛö).
  • pressure-controlled ventilation
    ¾Ð·ÂÁ¶Àýȯ±â
  • self controlled anesthesia
    ÀÚµ¿Á¦¾î¸¶Ãë.
  • accidental exposure
    »ç°í½ÃÇÇÆø, °ú½ÇÇÇÆø
  • acute exposure
    ±Þ¼ºÇÇÆø
  • chemical exposure
    È­ÇÐÀû ³ëÃâ<Æø·Î
  • chronic exposure
    ¸¸¼ºÇÇÆø
  • continuous exposure
    ¿¬¼ÓÇÇÆø
  • double exposure technique
    Áߺ¹ X¼±ÃÔ¿µ¼ú
  • exposure
    ÇÇÆø
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • genetic fine structure
    À¯Àü ¹Ì¼¼±¸Á¶(ë¶îîÚ°á¬Ï°ðã)
  • Greek-key structure
    ±×¸®½º¿­¼è ±¸Á¶(ϰðã)
  • isodesmic structure
    ÀÌÁúµ¿°áÇÕ ±¸Á¶(ì¶òõÔÒÌ¿ùêϰðã)
  • L-shaped structure
    L-Çü(úþ)±¸Á¶(ϰðã)
  • L-type structure
    L-Çü(úþ)±¸Á¶(ϰðã)
  • membrane structure
    ¸·±¸Á¶(دϰðã)
  • noncovalent structure
    ºñ°ø À¯±¸Á¶(ÞªÍëêóϰðã)
  • primary structure
    ÀÏÂ÷±¸Á¶(ìéó­Ï°ðã)
  • protein structure
    ´Ü¹éÁú ±¸Á¶(Ó±ÛÜòõϰðã)
  • quaternary structure
    »çÂ÷(ÞÌó­) ±¸Á¶(ϰðã).
  • quinary structure
    ¿ÀÂ÷(çéó­) ±¸Á¶(ϰðã).
  • secondary structure
    ÀÌÂ÷ ±¸Á¶(ì£ó­Ï°ðã)
  • sigma structure
    ½Ã±×¸¶±¸Á¶(ϰðã)
  • solenoid structure
    ¼Ö·¹³ëÀÌµå ±¸Á¶(ϰðã)
  • super-secondary structure
    ÃÊÀÌÂ÷ ±¸Á¶(õ±ì£ó­Ï°ðã)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NR do not repeat [Lat. non repetatur]; nerve root; neural retina; neutral red; noise reduction; nonreac...
NV nausea and vomiting; negative variation; neovascularization; next visit; nonveteran; normal value; n...
CEA Carcino-Embryonic Antigen [HP 1825-6]
  ; Oncofetal Antigens
  ; Glycopro...
NA Avogadro constant or number; nalidixic acid; Narcotics Anonymous; network administrator; neuraminida...
NFIRS National Fire Incident Reporting System
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
NGRI Not Guilty by Reason of Insanity
NOS Not Otherwise Specified
NFP Not-for-profit
NOT Nucleus of the Optic Tract
PDD-NOS Pervasive Developmental Disorder Not Otherwise Specified
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • exposure dose
    Á¶»ç·®
  • exposure threshold
    ³ëÃâ ÇѰèÄ¡
  • exposure time per session
    ´ÜÀ§´ç ³ëÃ⠽ð£
  • long-term exposure
    Àå±â ³ëÃâ
  • maximum permissible exposure
    ÃÖ´ë Çã¿ë ³ëÃâ
  • mercury exposure
    ¼öÀº¿¡ÀÇ ³ëÃâ
  • patient exposure
    ȯÀÚ ³ëÃâ
  • permissible radiation exposure level
    »ç¼± ³ëÃâ Çã¿ë·®
  • pulp exposure
    Ä¡¼ö ³ëÃâ
  • radiant exposure limit
    ¹æ»ç ³ëÃâ ÇѰè
  • radiation exposure
    ¹æ»ç¼± ³ëÃâ, ¹æ»ç¼± Á¶»ç
  • short-term exposure
    ´Ü±â ³ëÃâ
  • subanesthetic exposure
    ¸¶Ãë ¿ªÇÏ ÇÇÆø
  • water-air exposure rate
    ¼ö°øÁßÁ¶»ç¼±·®ºñ, ¹°-°ø±âÁßÁ¶»ç¼±·®ºñ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
permissible exposure limit An occupational health standard to safeguard workers against dangerous contaminants in the workplace.
(05 Mar 2000)
prenatal exposure delayed effects Delayed effects on offspring of maternal or foetal prenatal exposure to drugs, radiation and other physical agents, manipulation, nutrition, stress, etc.
(12 Dec 1998)
short-term exposure limit The maximum concentration of a chemical to which workers may be exposed continuously for up to 15 minutes without danger to health or work efficiency and safety.
(05 Mar 2000)
dental pulp exposure The result of pathological changes in the hard tissue of a tooth caused by carious lesions, mechanical factors, or trauma, which render the pulp susceptible to bacterial invasion from the external environment.
(12 Dec 1998)
inhalation exposure The exposure to potentially harmful chemical, physical, or biological agents by inhaling them.
(12 Dec 1998)
occupational exposure The exposure to potentially harmful chemical, physical, or biological agents that occurs as a result of one's occupation.
(12 Dec 1998)
environmental exposure The exposure to potentially harmful chemical, physical, or biological agents in the environment or to environmental factors that may include ionizing radiation, pathogenic organisms, or toxic chemicals.
(12 Dec 1998)
exposure <radiobiology> A quantitative measure of x or gamma radiation at a certain place, based on its ability to produce ionisation in air. The former special unit of exposure was the roentgen (R). 1R = 2.58 x 10-4 C/kg. In the international system (SI unit), the special unit is coulomb per kilogram. (Exposure also is frequently used as a synonym for irradiation).
(16 Dec 1997)
exposure dose The radiation dose, expressed in roentgens, delivered at a point in free air.
Synonym: air dose.
(05 Mar 2000)
exposure keratitis Inflammation of the cornea resulting from irritation caused by inability to close the eyelids.
Synonym: lagophthalmic keratitis.
(05 Mar 2000)
exposure odds ratio <epidemiology> See Odds ratio.
(05 Dec 1998)
analgesia, patient-controlled Relief of pain, without loss of consciousness, through an analgesic agent administered by the patient. It has been used successfully to control postoperative pain, during labour, after burns, and in terminal care. The choice of agent, dose, and lockout interval greatly influence effectiveness. The potential for overdose can be minimised by combining small bolus doses with a mandatory interval between successive doses (lockout interval).
(12 Dec 1998)
randomised controlled trial A clinical trial that involves at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Treatment allocations using coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are not truly randomised and a trial employing any of these techniques for patient assignment is designated simply a controlled clinical trial.
(12 Dec 1998)
randomised controlled trials Clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Treatment allocations using coin flips, odd-even numbers, patient social security numbers, days of the week, medical record numbers, or other such pseudo- or quasi-random processes, are not truly randomised and trials employing any of these techniques for patient assignment are designated simply controlled clinical trials.
(12 Dec 1998)
patient controlled analgesia <anaesthetics, procedure> Self-administration of analgesics by a patient instructed in doing so, usually refers to self-dosing with intravenous opioid (for example, morphine) administered by means of a programmable pump.
(16 Dec 1997)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • building
    ºôµù
  • Empire State Building
    ¿¥ÆÄÀÌ¾î ½ºÅ×ÀÌÆ® ºôµù(´º¿å½Ã¿¡ ÀÖ´Â,Áö»ó102ÃþÀÇ °íÃþ °Ç¹°,ÅÚ·¹ºñÁ¯ žÀ» Æ÷ÇÔÇÑ ³ôÀ̴¾à 449¹ÌÅÍ)
  • building
    °Ç¹°;°ÇÃà
  • building block
    ÁýÁþ±â³ª¹«
  • building line
    (µµ·Î µûÀ§¿¡ ÀÓÇÏ´Â)°ÇÃàÁ¦ÇѼ±
  • building lot
    °ÇÃà¿ë´ëÁö
  • image building
    (±¤°íµî¿¡ ÀÇÇÑ)À̹ÌÁö Çü¼º
  • model building
    ¸ðµ¨ ±¸¼º
  • ribbon building
    ´ë»ó °ÇÃà(RIBBON DEVELOPMENT¿¡ µû¸¥)
  • structure
    ±¸Á¶,Á¶Á÷,°ÇÃà(¹°)
  • constituent structure
    ±¸¼º¿ä¼Ò ±¸Á¶
  • cryptoexplosion structure
    ÀǺÐÈ­ ±¸Á¶
  • deep structure
    ½ÉÃþ ±¸Á¶((º¯Çü)»ý¼º ¹®¹ý¿¡¼­ ¹®ÀåÀÇ Àǹ̸¦ °áÁ¤ÇÏ´Â ½É¸®Àû ½ÇÀç·Î¼­ÀÇ ±âÀú ±¸Á¶)
  • fine structure
    ¹Ì¼¼±¸Á¶
  • molecular structure
    ºÐÀÚ ±¸Á¶
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á